{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T04:05:40Z","timestamp":1779509140155,"version":"3.53.1"},"reference-count":30,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DD&amp;T"],"published-print":{"date-parts":[[2026,4,30]]},"DOI":"10.5582\/ddt.2026.01007","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T22:09:24Z","timestamp":1777154964000},"page":"155-164","source":"Crossref","is-referenced-by-count":0,"title":["Chemotherapy combined targeted therapy has a potential benefit on the survival of advanced intrahepatic cholangiocarcinoma"],"prefix":"10.5582","volume":"20","author":[{"given":"Jian","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Hepatobiliary Surgery, Nanchuan Hospital of Chongqing Medical University, Chongqing, China."},{"name":"Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tengqian","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, the First Affiliated Hospital of Army Medical University, Chongqing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Liao","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"He","sequence":"additional","affiliation":[{"name":"Sichuan College of Traditional Chinese Medicine, Mianyang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Massarweh NN, El-Serag HB. Epidemiology of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Cancer Control. 2017; 24:1073274817729245.","DOI":"10.1177\/1073274817729245"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer. Lancet. 2021; 397:428-444.","DOI":"10.1016\/S0140-6736(21)00153-7"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Amini N, Ejaz A, Spolverato G, Kim Y, Herman JM, Pawlik TM. Temporal trends in liver-directed therapy of patients with intrahepatic cholangiocarcinoma in the United States: a population-based analysis. J Surg Oncol. 2014; 110:163-170.","DOI":"10.1002\/jso.23605"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. de Jong MC, Nathan H, Sotiropoulos GC, <i>et al.<\/i> Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol. 2011; 29:3140-3145.","DOI":"10.1200\/JCO.2011.35.6519"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J; ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010; 362:1273-1281.","DOI":"10.1056\/NEJMoa0908721"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Park J, Kim MH, Kim KP, Park DH, Moon SH, Song TJ, Eum J, Lee SS, Seo DW, Lee SK. Natural History and Prognostic Factors of Advanced Cholangiocarcinoma without Surgery, Chemotherapy, or Radiotherapy: A Large-Scale Observational Study. Gut Liver. 2009; 3:298-305.","DOI":"10.5009\/gnl.2009.3.4.298"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A, Nagino M, Kondo S, Nagaoka S, Funai J, Koshiji M, Nambu Y, Furuse J, Miyazaki M, Nimura Y. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer. 2010; 103:469-474.","DOI":"10.1038\/sj.bjc.6605779"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Morizane C, Okusaka T, Mizusawa J, <i>et al.<\/i> Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced\/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. Ann Oncol. 2019; 30:1950-1958.","DOI":"10.1093\/annonc\/mdz402"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Ioka T, Kanai M, Kobayashi S, <i>et al.<\/i> Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA). J Hepatobiliary Pancreat Sci. 2023; 30:102-110.","DOI":"10.1002\/jhbp.1219"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Valle JW, Wasan H, Johnson P, <i>et al.<\/i> Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study. Br J Cancer. 2009; 101:621-627.","DOI":"10.1038\/sj.bjc.6605211"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Valle JW, Wasan H, Lopes A, <i>et al.<\/i> Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial. Lancet Oncol. 2015; 16:967-978.","DOI":"10.1016\/S1470-2045(15)00139-4"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Oh DY, He AR, Bouattour M, <i>et al<\/i>. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study. Lancet Gastroenterol Hepatol. 2024; 9:694-704.","DOI":"10.1016\/S2468-1253(24)00095-5"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Kelley RK, Ueno M, Yoo C, <i>et al.<\/i> Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023; 401:1853-1865.","DOI":"10.1016\/S0140-6736(23)00727-4"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Banales JM, Marin JJG, Lamarca A, <i>et al<\/i>. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020; 17:557-588.","DOI":"10.1038\/s41575-020-0310-z"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Feng Y, Zhao M, Wang L, Li L, Lei JH, Zhou J, Chen J, Wu Y, Miao K, Deng CX. The heterogeneity of signaling pathways and drug responses in intrahepatic cholangiocarcinoma with distinct genetic mutations. Cell Death Dis. 2024; 15:34.","DOI":"10.1038\/s41419-023-06406-7"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Xiao H, Wang J, Weng Z, <i>et al<\/i>. A histopathology-based artificial intelligence system assisting the screening of genetic alteration in intrahepatic cholangiocarcinoma. Br J Cancer. 2025; 132:195-202.","DOI":"10.1038\/s41416-024-02910-5"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Smolenschi C, Blanc JF, Lancry A, Klajer E, Debaillon-Vesque A, Vantelon JM, Boileve A, Valery M, Hollebecque A, Ducreux M, Decraecker M. Real-world efficacy of zanidatamab in patients with HER2 positive advanced biliary tract cancers. Eur J Cancer. 2025; 222:115432.","DOI":"10.1016\/j.ejca.2025.115432"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Kudo M, Ren Z , Guo Y, <i>et al<\/i>. Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study. Lancet. 2025; 405:203-215.","DOI":"10.1016\/S0140-6736(24)02575-3"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Jiang N, Zhang Z, Yin X, Qiu H, Yan W, Hao Y, Yang W, Li H, Xu A, Mu K. Systemic chemotherapy plus transarterial chemoembolization versus systemic chemotherapy alone for unresectable intrahepatic cholangiocarcinoma: a multicenter retrospective cohort study. Radiol Med. 2024; 129:631-642.","DOI":"10.1007\/s11547-024-01781-3"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. He M, Jiang N, Yin X, Xu A, Mu K. Conventional and drug-eluting beads transarterial chemoembolization in patients with unresectable intrahepatic cholangiocarcinoma: a systematic review and pooled analysis. J Cancer Res Clin Oncol. 2023; 149:531-540.","DOI":"10.1007\/s00432-022-04485-1"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Brown DB, Geschwind JF, Soulen MC, Millward SF, Sacks D. Society of Interventional Radiology position statement on chemoembolization of hepatic malignancies. J Vasc Interv Radiol. 2009; 20(7 Suppl):S317-S323.","DOI":"10.1016\/j.jvir.2009.04.015"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Gusani NJ, Balaa FK, Steel JL, Geller DA, Marsh JW, Zajko AB, Carr BI, Gamblin TC. Treatment of unresectable cholangiocarcinoma with gemcitabine-based transcatheter arterial chemoembolization (TACE): a single-institution experience. J Gastrointest Surg. 2008; 12:129-137.","DOI":"10.1007\/s11605-007-0312-y"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Luo S, Xiang Z, Li M, Zhao C, Yan H, Huang M. Clinical Effectiveness of Drug-Eluting Microsphere Transcatheter Arterial Chemoembolization Combined with First-Line Chemotherapy as the Initial Treatment for Patients with Unresectable Intrahepatic Cholangiocarcinoma. J Vasc Interv Radiol. 2024; 35:1616-1625.","DOI":"10.1016\/j.jvir.2024.08.006"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Boehm LM, Jayakrishnan TT, Miura JT, Zacharias AJ, Johnston FM, Turaga KK, Gamblin TC. Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma. J Surg Oncol. 2015; 111:213-220.","DOI":"10.1002\/jso.23781"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Squires MH, Cloyd JM, Dillhoff M, Schmidt C, Pawlik TM. Challenges of surgical management of intrahepatic cholangiocarcinoma. Expert Rev Gastroenterol Hepatol. 2018; 12:671-681.","DOI":"10.1080\/17474124.2018.1489229"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Wang Y, Shang P, Xu C, Dong W, Zhang X, Xia Y, Sui C, Yang C. Novel genetic alterations in liver cancer distinguish distinct clinical outcomes and combination immunotherapy responses. Front Pharmacol. 2024; 15:1416295.","DOI":"10.3389\/fphar.2024.1416295"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Chen L, Han R, Song T, Song P, Tang W. Perioperative and precision strategies in resectable intrahepatic cholangiocarcinoma. Glob Health Med. 2025; 7:347-351.","DOI":"10.35772\/ghm.2025.01102"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Heuser C, Diekmann A, Kowalski C, Enders A, Conrad R, Pfaff H, Ansmann L, Ernstmann N. Health literacy and patient participation in multidisciplinary tumor conferences in breast cancer care: a multilevel modeling approach. BMC Cancer. 2019; 19:330.","DOI":"10.1186\/s12885-019-5546-z"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Yu Y, You Y, Duan Y, <i>et al<\/i>. Multi-omics approaches for identifying the PANoptosis signature and prognostic model <i>via<\/i> a multimachine-learning computational framework for intrahepatic cholangiocarcinoma. Hepatology. 2026; 83:466-483.","DOI":"10.1097\/HEP.0000000000001352"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Zhang XF, Beal EW, Bagante F, <i>et al.<\/i> Early versus late recurrence of intrahepatic cholangiocarcinoma after resection with curative intent. Br J Surg. 2018; 105:848- 856.","DOI":"10.1002\/bjs.10676"}],"container-title":["Drug Discoveries &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/20\/2\/20_2026.01007\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T03:28:08Z","timestamp":1779506888000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/20\/2\/20_2026.01007\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5582\/ddt.2026.01007","relation":{},"ISSN":["1881-7831","1881-784X"],"issn-type":[{"value":"1881-7831","type":"print"},{"value":"1881-784X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"article-number":"2026.01007"}}